As established model substances we used the cardiotonic steroid and Na+/K+-ATPase inhibitor ouabain ([16–18]) as well as the actin-affecting cytochalasin D [19] as migration inhibitors and the epidermal growth factor (EGF) as a migration enhancer ([16,20]) of A549 human lung carcinoma cells [16,21,22], respectively, to demonstrate the applicability of this protocol. This evidence concerns the gene EGF and lung carcinoma.